Evaluating the anti-leishmania activity of Lucilia sericata and Sarconesiopsis magellanica blowfly larval excretions/secretions in an in vitro model

Leishmaniasis is a vector-borne disease caused by infection by parasites from the genus Leishmania. Clinical manifestations can be visceral or cutaneous, the latter mainly being chronic ulcers. This work was aimed at evaluating Calliphoridae Lucilia sericata- and Sarconesiopsis magellanica-derived l...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2018
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23674
Acceso en línea:
https://doi.org/10.1016/j.actatropica.2017.09.033
https://repository.urosario.edu.co/handle/10336/23674
Palabra clave:
Antileishmanial agent
Meglumine antimonate
Insect protein
Disease
Fly
Larva
Modeling
Parasite
Amastigote
Antiprotozoal activity
Article
Calliphoridae
Cell viability assay
Concentration (parameters)
Concentration response
Controlled study
Cytotoxicity
Excretion
Host cell
Human
Human cell
Ic50
In vitro study
Larva
Lc50
Leishmania panamensis
Leishmaniasis
Lucilia sericata
Macrophage
Microscopy
Nonhuman
Parasite load
Promastigote
Quantitative analysis
Resazurin assay
Sarconesiopsis magellanica
Secretion (process)
Survival index
U-937 cell line
Animal
Diptera
Drug effects
Larva
Leishmania
Parasitology
Calliphoridae
Leishmania panamensis
Lucilia sericata
Animals
Diptera
Insect proteins
Larva
Leishmania
Macrophages
Parasite load
Ic50
Larval excretion/secretion
Leishmania panamensis
Lucilia sericata
Sarconesiopsis magellanica
U937
Rights
License
Abierto (Texto Completo)
Description
Summary:Leishmaniasis is a vector-borne disease caused by infection by parasites from the genus Leishmania. Clinical manifestations can be visceral or cutaneous, the latter mainly being chronic ulcers. This work was aimed at evaluating Calliphoridae Lucilia sericata- and Sarconesiopsis magellanica-derived larval excretions and secretions' (ES) in vitro anti-leishmanial activity against Leishmania panamensis. Different larval-ES concentrations from both blowfly species were tested against either L. panamensis promastigotes or intracellular amastigotes using U937-macrophages as host cells. The Alamar Blue method was used for assessing parasite half maximal inhibitory concentration (IC50) and macrophage cytotoxicity (LC50). The effect of larval-ES on L. panamensis intracellular parasite forms was evaluated by calculating the percentage of infected macrophages, parasite load and toxicity. L. sericata–derived larval-ES L. panamensis macrophage LC50 was 72.57 ?g/mL (65.35–80.58 ?g/mL) and promastigote IC50 was 41.44 ?g/mL (38.57–44.52 ?g/mL), compared to 34.93 ?g/mL (31.65–38.55 ?g/mL) LC50 and 23.42 ?g/mL (22.48–24.39 ?g/mL) IC50 for S. magellanica. Microscope evaluation of intracellular parasite forms showed that treatment with 10 ?g/mL L. sericata ES and 5 ?g/mL S. magellanica ES led to a decrease in the percentage of infected macrophages and the amount of intracellular amastigotes. This study produced in vitro evidence of the antileishmanial activity of larval ES from both blowfly species on different parasitic stages and showed that the parasite was more susceptible to the ES than it's host cells. The antileishmanial effect on L. panamensis was more evident from S. magellanica ES. © 2017 Elsevier B.V.